Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Control Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

NCT05808322 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05808322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05808322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Control Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
May 15, 2023
Completion date
December 31, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19